Summary:
Pacific Research Partners is conducting a Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the treatment of HSDD (with or without decreased arousal) in premenopausal females.
Qualified Participants Must:
• Have experienced a decrease in your sexual desire over time
•
Feel distressed about this decreased sexual desire
•
Have been in a committed relationship for at least six months
•
Have not yet gone through menopause
Qualified Participants May Receive:
All study-related medical care at no cost, be seen by a study doctor who understands decreased sexual desire, will help evaluate a ‘take as needed’ treatment taken before sexual activity, and may be reimbursed for time and travel.